Luis Nieves, MD
Interventional Pain Medicine · Hurst, TXNPI 1801089503
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Abbott accounts for 82.2% of it on its own, with 45 other manufacturers making up the rest.
Across 999 payments — averaging $40.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$33K
- Genesys Orthopedics Systems, L.L.C.$1K
- Boston Scientific$1K
- Collegium Pharmaceutical, Inc.$832
- Spinal Simplicity, LLC$692
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$534
- plus $3K from 40 others
What the payments were for
- Consulting fees$14,73836%
- Speaking & faculty fees$3,0157%
- Travel & lodging$1,3133%
- Food & beverage$21,07752%
- Education$3661%
- Gifts$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$17,756
- Proclaim Family of SCS IPGs$2,128
- PROTG$1,500
- SACROILIAC JOINT FUSION SYSTEM$1,103
- OCTRODE$749
- HA MINUTEMAN G3-R$487
- Proclaim IPG$269
- GENERAL PAIN MANAGEMENT$143
How this compares
$40,523 in reported general payments places this provider in the 85th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,693 | $72,963 |
| BelbucaBuprenorphine Hcl | 37 | $31,002 |
| Xtampza ErOxycodone Myristate | 29 | $13,865 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 292 | $12,159 |
| MovantikNaloxegol Oxalate | 28 | $11,398 |
| Buprenorphine | 44 | $10,738 |
| LinzessLinaclotide | 11 | $6,063 |
| Lidocaine | 44 | $5,112 |
| Pregabalin | 169 | $4,860 |
| Naloxone Hcl | 59 | $3,842 |
| Gabapentin | 234 | $3,342 |
| Oxycodone Hcl | 137 | $2,893 |
| Cyclobenzaprine Hcl | 201 | $2,004 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 79 | $1,860 |
| Tramadol Hcl | 119 | $1,778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $832 | $44,86666 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $44 | $11,92483 claims |
| Redhill Biopharma Inc.Movantik | $15 | $11,39828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Hurst
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.1M
- Chad StephensSouthlake$1M
- Ankur KhoslaShenandoah$277K
- Brian RichDecatur$245K
- Brian BruelHouston$219K
- Bolkar SahinlerLubbock$188K
- Timothy RatinoFort Worth$139K
- Genaro GutierrezAustin$125K
- Thomas WhiteShenandoah$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.